FLT3 and acute myeloid leukemia: Approval was based on the phase 3 RATIFY/CALGB 10603 trial, which demonstrated improved survival with the addition of midostaurin to intensive chemotherapy followed by single-agent maintenance therapy in patients aged <60 years with newly diagnosed, FLT3-mutated AML.